英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
---|---|---|---|---|---|---|
RO 3306
|
872573-93-8 |
2-[[(噻吩-2-基)甲基]氨基]-5-[1-(喹啉-6-基)甲-(Z)-亚基]噻唑-4-酮
|
2-[[(噻吩-2-基)甲基]氨基]-5-[1-(喹啉-6-基)甲-(Z)-亚基]噻唑-4-酮;RO3306;RO 3306;2-[[(噻吩-2-基)甲基]氨基]-5-[1-(喹啉-6-基)甲-(Z)-亚基]噻唑-4-酮(RO 3306);CS-770
|
C18H13N3OS2 |
351.44532 | |
RITA (NSC 652287)
|
213261-59-7 |
RITA, >99%
|
NSC-652287;NSC 652287;5,5'-(2,5-呋喃二基)二-2-噻吩甲醇;5,5-呋喃二基)二-2-噻吩甲醇 RITA;5-呋喃二基)二-2-噻吩甲醇
|
C14H12O3S2 |
292.37328 | 200-256-5 |
RGFP 966
|
1357389-11-7 |
RGFP966
|
(2E)-N-(2-氨基-4-氟苯基)-3-[1-(3-苯基-2-丙烯-1-基)-1H-吡唑-4-基]-2-丙烯酰胺;CS-871;RGFP966;RGFP-966
|
C21H19FN4O |
362.400163 | |
PluriSIn #1-NSC 14613 | Pluripotent cell-specific inhibitor #1
|
91396-88-2 |
NSC 14613
|
NSC 14613;NSC-14613;NSC14613;N'-二苯基-4-碳酰肼;N'-PHENYLISONICOTINOHYDRAZIDE;4-吡啶羧酸 2-苯基酰肼;4-吡啶羧酸 2-苯基酰肼(NSC 14613);异烟酸2-苯肼;异烟酸2-苯肼>98%;4-吡啶甲酸2-苯肼
|
C12H11N3O |
213.23524 | 804-702-5 |
N-(2,3-Dihydro-7,8-dimethoxyimidazo[1,2-c]quinazolin-5-yl)-3-pyridinecarboxamide
|
677338-12-4 |
N-(2,3-二氢-7,8-二甲氧基咪唑并[1,2-C]喹唑啉-5-基)-3-吡啶甲酰胺
|
N-(2,3-二氢-7,8-二甲氧基咪唑并[1,2-C]喹唑啉-5-基)-3-吡啶甲酰胺;2-C]喹唑啉-5-基)-3-吡啶甲酰胺;CS-433;8-二甲氧基咪唑并[1
|
C18H17N5O3 |
351.37 | |
PI-103 Hydrochloride
|
371935-79-4 |
PI-103, HYDROCHLORIDE SALT, >99%
|
3-[4-(4-吗啉基)吡啶并[3',2':4,5]呋喃并[3,2-D]嘧啶-2-基]苯酚单盐酸盐;PI 103 HYDROCHLORIDE;PI103 HYDROCHLORIDE
|
C19H17ClN4O3 |
384.81628 | |
PF-06447475
|
1527473-33-1 |
PF-06447475
|
PF-06447475>98%;CS-1734;PF 06447475;PF06447475;3-[4-(4-吗啉基)-7H-吡咯并[2,3-D]嘧啶-5-基]苯甲腈
|
C17H15N5O |
305.34 | |
PCI-34051
|
950762-95-5 |
N-羟基-1-(4-甲氧基苄基)-1H-吲哚-6-甲酰胺
|
N-羟基-1-(4-甲氧基苄基)-1H-吲哚-6-甲酰胺;PCI-34051;PCI 34051
|
C17H16N2O3 |
296.32054 | |
Palomid 529 (P529)
|
914913-88-5 |
PALOMID 529 (P529)
|
P529;PALOMID529;P 529;PALOMID-529;P-529;8-(1-羟基乙基)-2-甲氧基-3-[(4-甲氧基苯基)甲氧基]-6H-二苯并[B,D]吡喃-6-酮;-(1-羟基乙基)-2-甲氧基-3-[(4-甲氧基苯基)甲氧基]-6H-二苯并[B,D]吡喃-6-酮;PALOMID 529,一种有效的MTORC1和MTORC2复合物的抑制剂
|
C24H22O6 |
406.42788 | 806-313-6 |
Nexturastat A
|
1403783-31-2 |
4-((1-BUTYL-3-PHENYLUREIDO)METHYL)-N-HYDROXYBENZAMIDE
|
4-((1-BUTYL-3-PHENYLUREIDO)METHYL)-N-HYDROXYBENZAMIDE;4-[[丁基[(苯基氨基)羰基]氨基]甲基]-N-羟基苯甲酰胺;CS-1289;NEXTURASTAT A>97%
|
C19H23N3O3 |
341.40422 | |
MK-2206 di hydrochloride
|
1032350-13-2 |
MK-2206 2HCl
|
8-[4-(1-氨基环丁基)苯基]-9-苯基-1,2,4-三...;MK-2206 2HCL;MK2206;CS-260;MK 2206 2HCL;MK2206 2HCL;MK-2206 DIHYDROCHLORIDE;MK2206 DIHYDROCHLORIDE;(8-[4-(1-氨基环丁基)苯基]-9-苯基-2H-[1,4]三唑并[3,4-F][1,6]萘啶-3-酮)二盐酸盐;MK-2206 二盐酸盐,一种变构 AKT 抑制剂;MK 2206 2HCL;MK2206 2HCL;8-[4-(1-氨基环丁基)苯基]-9-苯基-1,4-三唑并[3,6]萘啶-3(2H)-酮二盐酸盐
|
C25H21N5O.2(HCL) |
407.46714 | |
MHY1485
|
326914-06-1 |
MHY1485
|
MHY1485;4,6-dimorpholino-N-(4-nitrophenyl)-1,3,5-triazin-2-amine;4,6-Di-4-morpholinyl-N-(4-nitrophenyl)-1,3,5-triazin-2-amine
|
C17H21N7O4 |
387.39314 | |
LY 333531 hydrochloride-Ruboxistaurin
|
169939-93-9 |
鲁伯斯塔盐酸盐
|
鲁伯斯塔盐酸盐;芦布妥林
|
C28H29ClN4O3 |
505.01 | |
LY-2584702 (tosylate salt)
|
1082949-68-5 |
N/A
|
LY-2584702;LY 2584702;LYS6K2;LY-2584702 对甲苯磺酸盐;CS-2145
|
C28H27F4N7O3S |
617.617693 | |
LW6
|
934593-90-5 |
LW 6
|
CAY 10585;CAY-10585;CAY10585;LW6
|
C26H29NO5 |
435.51216 | |
LEE011
|
1211441-98-3 |
LEE011
|
瑞柏司可里布;LEE011 瑞柏司可里布;LEE011 瑞柏司可里布 50MG
|
C23H30N8O |
434.5373 | 1592732-453-0 |
KRCA 0008
|
1472795-20-2 |
N/A
|
CS-1715
|
C30H37ClN8O4 |
609.128 | |
JIB-04
|
199596-05-9 |
5-氯-2(1H)-吡啶酮 (2E)-(苯基-2-吡啶基亚甲基)腙
|
5-氯-2(1H)-吡啶酮 (2E)-(苯基-2-吡啶基亚甲基)腙>97%;CS-1447;NSC693627;JIB04;JIB 04;NSC-693627;JIB-04;JIB04;5-氯-2(1H)-吡啶酮 (2E)-(苯基-2-吡啶基亚甲基)腙;(E)-5-CHLORO-2-(2-(PHENYL(PYRIDIN-2-YL)METHYLENE)HYDRAZINYL)PYRIDINE
|
C17H13ClN4 |
308.76492 | |
ISRIB (trans-isomer)
|
1597403-47-8 |
ISRIB(TRANS-ISOMER) 抑制剂
|
ISRIB (TRANS-ISOMER)>98%;ISRIB(TRANS-ISOMER)抑制剂
|
C22H24Cl2N2O4 |
451.34296 | |
IMD 0354
|
978-62-1 |
N-[3,5-双(三氟甲基)苯基]-5-氯-2-羟基苯甲酰胺
|
IMD 0354;IMD-0354;IKK-2 INHIBITOR V;IMD 0354;IMD0354;N-[3,5-双(三氟甲基)苯基]-5-氯-2-羟基苯甲酰胺;IMD-0354,一种合成的选择性NF-KB 抑制剂
|
C15H8NO2F6Cl |
383.67292 |